Immunology News and Research

Latest Immunology News and Research

NIH awards research grants for NYU Langone Medical Center

NYU Langone Medical Center has been awarded more than $30 million in research grants from the National Institute of Health (NIH) for 86 research projects being conducted at NYU School of Medicine across a broad range of basic science and clinical departments.

14 Oct 2009

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Sosei Group Corporation, a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties.

14 Oct 2009

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

The National Institutes of Health (NIH) has awarded a "Grand Opportunity" grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease (GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease (HD) and to develop potential therapies.

14 Oct 2009

Talecris Biotherapeutics Holdings to raise $550 million through private placement

Talecris Biotherapeutics Holdings Corp. today announced that it has commenced an offering through a private placement of $550 million aggregate principal amount of senior notes due 2016 (the “Notes”). Talecris intends to use the proceeds from the offering to repay its First and Second Lien Term Loans, repay a portion of borrowings under its Revolving Credit Facility, and to pay related fees and expenses.

13 Oct 2009

NIH funds the University of California's consortium for immune disorder research

The University of California, San Francisco has been designated to lead a new consortium that will study a group of severe immune disorders known as primary immunodeficiencies and aims to improve treatment for these often life-threatening diseases. The Primary Immune Deficiency Treatment Consortium comprises 13 centers throughout the United States and has a $6.25 million funding commitment over five years from the National Institutes of Health.

13 Oct 2009

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

ImaginAb, Inc. and BZL Biologics, LLC have concluded a sublicense of BZL's PSMA/huJ591 antibody technology for the field of diagnostic imaging for PET and SPECT. "ImaginAb is pleased to have completed this [sub]licensing agreement with BZL as we believe that huJ591 will form the basis of an excellent clinical product for the diagnosis and management of prostate cancer.

12 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

U.S. women with RA feel less self-confident in their sex-life, reveals survey

A new survey of U.S. women living with rheumatoid arthritis (RA) published today reveals that RA has a clear emotional impact on people living with the disease, with loss of self-confidence seen in their sex lives, in the workplace, and in their social lives.

12 Oct 2009

Researchers find SNARE-like protein system to help bacteria avoid cell destruction

Infectious diseases currently cause about one-third of all human deaths worldwide, more than all forms of cancer combined. Advances in cell biology and microbial genetics have greatly enhanced understanding of the cause and mechanisms of infectious diseases.

12 Oct 2009

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

In response to new economic and regulatory realities, CytoDyn, Inc. has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS.

9 Oct 2009

New York Governor participates in roundtable discussion on stem cell research

Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today. Allen M. Spiegel, M.D., the Marilyn and Stanley M. Katz Dean of Einstein, and eight stem cell researchers discussed advances in medical therapies and treatments that Einstein scientists have been investigating since receiving more than $14 million in State funding for stem cell research.

9 Oct 2009

NIAID awards $60M for research contracts to discover new adjuvants

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded six new research contracts to discover and characterize novel adjuvants, substances that can be added to vaccines to enhance the protective immune response they induce.

9 Oct 2009

Aging of the immune system coincides with higher rates of cancer in the elderly

Elderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease. The challenge is to boost their immune response to cancer vaccines, because like the rest of our organs, our immune system ages and gradually becomes less efficient as we get older.

9 Oct 2009

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

St. Jude Children's Research Hospital investigators have discovered how destructive immune cells gain access to insulin-producing cells and help cause diabetes.

9 Oct 2009

Human stem cells advance cancer vaccine research

Scientists from the United States and China have revealed the potential for human stem cells to provide a vaccination against colon cancer, reports a study published in STEM CELLS.

8 Oct 2009

Elderly cancer patients need custom-made treatment to combat the disease

8 Oct 2009

CEL-SCI Corporation reports on its dendritic H1N1 treatment

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special editorial report about CEL-SCI Corporation's presentation of data about the company's dendritic H1N1 treatment, being developed as a treatment for H1N1 hospitalized patients.

8 Oct 2009

Talecris Biotherapeutics closes initial public offering of common stock

Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) (“Talecris” or the “Company”) today announced the closing on October 6 of its initial public offering of shares of common stock, which was priced on September 30 at a public offering price of $19.00 per share.

8 Oct 2009

Experts to develop effective surveillance system to monitor emerging infections at global level

Avian influenza (H5N1), rabies, plague, Bovine Spongiform Encephalopathy (BSE), and more recently swine flu (H1N1) are all examples of diseases that have made the leap from animals to humans.

8 Oct 2009

New study leads to the development of first prophylactic treatment for leishmania

Leishmania is a deadly parasitic disease that affects over 12 million people worldwide, with more than 2 million new cases reported every year. Until recently, scientists were unsure exactly how the parasite survives inside human cells. That mystery has now been solved according to a new study published in Science Signaling by a team led by Dr. Martin Olivier - a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University.

7 Oct 2009

Immunology News and Research

Latest Immunology News and Research

NIH awards research grants for NYU Langone Medical Center

Sosei Group assigns its SD281 drug discovery programme to Biocopea

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

Talecris Biotherapeutics Holdings to raise $550 million through private placement

NIH funds the University of California's consortium for immune disorder research

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

Wake Forest University School of Medicine honours researchers

U.S. women with RA feel less self-confident in their sex-life, reveals survey

Researchers find SNARE-like protein system to help bacteria avoid cell destruction

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

New York Governor participates in roundtable discussion on stem cell research

NIAID awards $60M for research contracts to discover new adjuvants

Aging of the immune system coincides with higher rates of cancer in the elderly

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

Human stem cells advance cancer vaccine research

Elderly cancer patients need custom-made treatment to combat the disease

CEL-SCI Corporation reports on its dendritic H1N1 treatment

Talecris Biotherapeutics closes initial public offering of common stock

Experts to develop effective surveillance system to monitor emerging infections at global level

New study leads to the development of first prophylactic treatment for leishmania

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog